Precision Delivery. Proprietary Platforms. Proven Absorption.
Avant Labs develops and licenses formulation and device platforms that stabilize and provide effective, targeted absorption of next-generation bio-actives.
Platform Architecture
Two Platforms. One Mission.
Avant Labs operates two independent, IP-protected delivery technology platforms — each engineered for a distinct absorption pathway, each capable of standalone licensing or co-formulation.
Buccal Thin-Film Delivery
AbsorbWell™
Sublingual and buccal thin-film matrices that bypass first-pass metabolism for rapid, high-bioavailability absorption of bio-actives. Engineered for precision dosing, stability under ambient conditions, and patient-compliant administration.
Topical Skin-Binding & Barrier Delivery
Issengard™ / Beyond ReLeaf™
Proprietary topical carrier systems that bind active compounds to the dermal barrier for sustained, localized delivery without systemic exposure. Formulated for stability, skin compatibility, and measurable dermal retention.
Investment Thesis
Why Avant Labs
IP-Protected Platforms
Defensible Moat
Both delivery platforms are protected by a growing patent portfolio covering formulation methods, carrier compositions, and device configurations. Licensing rights are structured for exclusivity by vertical.
Dual Revenue Architecture
Licensing + Direct
Platform licensing to established brands generates recurring royalty revenue. Direct-to-market product lines under Avant Labs brands provide margin-rich revenue alongside the licensing business.
Next-Generation Bio-Actives
$87B+ TAM
The global nutraceutical and cosmeceutical delivery market is underserved by precision absorption technology. Avant Labs platforms are formulated for the compounds that legacy delivery systems cannot effectively stabilize or deliver.
Traction
Early Validation. Accelerating Pipeline.
1
Patent Application Filed
Across both platforms
8
Influencer MOUs Drafted
Licensing & co-formulation
$2.5M
Projected Pipeline Value
LOI stage
8
Formulations in Development
Across both platforms
Placeholder metrics — replace with verified data before investor distribution.
For Investors
Seed Round Now Open
Avant Labs is raising a seed round. Review our technology thesis, IP portfolio, and market opportunity. Institutional and strategic investors welcome.
For Creators & Brands
Build With Our Platforms
Partner with a delivery technology platform built for the next wave of bio-active products. White-label, co-formulation, and creator programs available.